Literature DB >> 12740095

Viable osteogenic cells are obligatory for tissue-engineered ectopic bone formation in goats.

M C Kruyt1, J D de Bruijn, C E Wilson, F C Oner, C A van Blitterswijk, A J Verbout, W J A Dhert.   

Abstract

In this study we investigated the bone-forming capacity of tissue-engineered (TE) constructs implanted ectopically in goats. As cell survival is questionable in large animal models, we investigated the significance of vitality, and thus whether living cells instead of only the potentially osteoinductive extracellular matrix are required to achieve bone formation. Vital TE constructs of porous hydroxyapatite (HA) covered with differentiated bone marrow stromal cells (BMSCs) within an extracellular matrix (ECM) were compared with identical constructs that were devitalized before implantation. The devitalized implants did contain the potentially osteoinductive ECM. Furthermore, we evaluated HA impregnated with fresh bone marrow and HA only. Two different types of HA granules with a volume of approximately 40 microm were investigated: HA70/800, a microporous HA with 70% interconnected macroporosity and an average pore size of 800 microm, and HA60/400, a smooth HA with 60% interconnected macropores and an average size of 400 microm. Two granules of each type were combined and then treated as a single unit for cell seeding, implantation, and histology. The tissue-engineered samples were obtained by seeding culture-expanded goat BMSCs on the HA and subsequently culturing these constructs for 6 days to allow cell differentiation and ECM formation. To devitalize, TE constructs were frozen in liquid nitrogen according to a validated protocol. Fresh bone marrow impregnation was performed perioperatively (4 mL per implant unit). All study groups were implanted in bilateral paraspinal muscles. Fluorochromes were administered at three time points to monitor bone mineralization. After 12 weeks the units were explanted and analyzed by histology of nondecalcified sections. Bone formation was present in all vital tissue-engineered implants. None of the other groups showed any bone formation. Histomorphometry indicated that microporous HA70/800 yielded more bone than did HA60/400. Within the newly formed bone, the fluorescent labels showed that mineralization had occurred before 5 weeks of implantation and was directed from the HA surface toward the center of the pores. In conclusion, tissue-engineered bone formation in goats can be achieved only with viable constructs of an appropriate scaffold and sufficient BMSCs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12740095     DOI: 10.1089/107632703764664792

Source DB:  PubMed          Journal:  Tissue Eng        ISSN: 1076-3279


  39 in total

Review 1.  Vascularized bone tissue engineering: approaches for potential improvement.

Authors:  Lonnissa H Nguyen; Nasim Annabi; Mehdi Nikkhah; Hojae Bae; Loïc Binan; Sangwon Park; Yunqing Kang; Yunzhi Yang; Ali Khademhosseini
Journal:  Tissue Eng Part B Rev       Date:  2012-09-04       Impact factor: 6.389

2.  Performance of evacuated calcium phosphate microcarriers loaded with mesenchymal stem cells within a rat calvarium defect.

Authors:  Guang-Zhen Jin; Joong-Hyun Kim; Jeong-Hui Park; Seong-Jun Choi; Hae-Won Kim; Ivan Wall
Journal:  J Mater Sci Mater Med       Date:  2012-04-27       Impact factor: 3.896

3.  Injectable PolyMIPE Scaffolds for Soft Tissue Regeneration.

Authors:  Robert S Moglia; Jennifer L Robinson; Andrea D Muschenborn; Tyler J Touchet; Duncan J Maitland; Elizabeth Cosgriff-Hernandez
Journal:  Polymer (Guildf)       Date:  2014-01-14       Impact factor: 4.430

4.  Multimaterial Dual Gradient Three-Dimensional Printing for Osteogenic Differentiation and Spatial Segregation.

Authors:  Brandon T Smith; Sean M Bittner; Emma Watson; Mollie M Smoak; Luis Diaz-Gomez; Eric R Molina; Yu Seon Kim; Carrigan D Hudgins; Anthony J Melchiorri; David W Scott; K Jane Grande-Allen; James J Yoo; Anthony Atala; John P Fisher; Antonios G Mikos
Journal:  Tissue Eng Part A       Date:  2019-12-27       Impact factor: 3.845

5.  In-vivo evaluation of subcutaneously implanted cell-loaded apatite microcarriers for osteogenic potency.

Authors:  Poon Nian Lim; Jason Feng; Zuyong Wang; Mark Chong; Toshiisa Konishi; Lay Geok Tan; Jerry Chan; Eng San Thian
Journal:  J Mater Sci Mater Med       Date:  2017-05-03       Impact factor: 3.896

6.  Sustained release of bone morphogenetic protein 2 via coacervate improves the osteogenic potential of muscle-derived stem cells.

Authors:  Hongshuai Li; Noah Ray Johnson; Arvydas Usas; Aiping Lu; Minakshi Poddar; Yadong Wang; Johnny Huard
Journal:  Stem Cells Transl Med       Date:  2013-07-24       Impact factor: 6.940

7.  Osteogenic and angiogenic potentials of monocultured and co-cultured human-bone-marrow-derived mesenchymal stem cells and human-umbilical-vein endothelial cells on three-dimensional porous beta-tricalcium phosphate scaffold.

Authors:  Yunqing Kang; Sungwoo Kim; Monica Fahrenholtz; Ali Khademhosseini; Yunzhi Yang
Journal:  Acta Biomater       Date:  2012-08-16       Impact factor: 8.947

8.  Clinical application of human mesenchymal stromal cells for bone tissue engineering.

Authors:  Anindita Chatterjea; Gert Meijer; Clemens van Blitterswijk; Jan de Boer
Journal:  Stem Cells Int       Date:  2010-11-11       Impact factor: 5.443

9.  Effect of autologous bone marrow stromal cell seeding and bone morphogenetic protein-2 delivery on ectopic bone formation in a microsphere/poly(propylene fumarate) composite.

Authors:  Diederik H R Kempen; Moyo C Kruyt; Lichun Lu; Clayton E Wilson; Anthony V Florschutz; Laura B Creemers; Michael J Yaszemski; Wouter J A Dhert
Journal:  Tissue Eng Part A       Date:  2009-03       Impact factor: 3.845

10.  Synergistic enhancement of ectopic bone formation by supplementation of freshly isolated marrow cells with purified MSC in collagen-chitosan hydrogel microbeads.

Authors:  Joel K Wise; Andrea I Alford; Steven A Goldstein; Jan P Stegemann
Journal:  Connect Tissue Res       Date:  2015-09-04       Impact factor: 3.417

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.